Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

1
Idera Pharmaceuticals Provides Update on Corporate Strategy and Outlook

2018-07-16 globenewswire
EXTON, Pa., July 16, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, is providing an update on the company’s corporate strategy and outlook following the recent termination of its proposed merger with BioCryst Pharmaceuticals.
IDRAW IDRA BCRX

5
Biotech Analysis Central Pharma News: Pfizer's Unit Separation, BioCryst's Merger Collapses, Scynexis' Positive Mid-Stage Results

2018-07-12 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
IDRAW IDRA PFE SCYX

10
American Airlines, Avon Products Plummet into Wednesday’s 52-Week Low Club

2018-07-11 247wallst
July 11, 2018: Here are four stocks trading with heavy volume among 63 equities making new 52-week lows in Wednesday’s session. On the NYSE decliners led advancers by about5 2.5 to 1 and on the Nasdaq, decliners led advancers by about 1.87 to 1.
FPI.PRB IDRAW AAL IDRA AVP FPI

2
BioCryst Shareholders Back Out of Idera Merger

2018-07-11 247wallst
Idera Pharmaceuticals Inc. (NASDAQ: IDRA) shares crumbled on Wednesday after BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) announced that it terminated their merger agreement.
IDRAW IDRA BCRX

11
Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More

2018-07-11 zacks
Positive data released by bigwig Biogen, Inc. (BIIB - Free Report) from a mid-stage study for the treatment of Alzheimer’s disease created a stir in the biotech sector last week. Among other news, Celgene Corporation (CELG - Free Report) reported positive data on a key pipeline candidate from a late-stage study while Axovant (AXON - Free Report) gained on yet another licensing deal.
XLRN CELGZ BIIB IDRAW BLT IDRA CELG BNTC BNIKF BCRX AXON BNTCW

3
Idera Pharma and BioCryst Pharma Get a Divorce Before the Wedding

2018-07-11 biospace
Idera Pharmaceuticals and BioCryst Pharmaceuticals originally planned on January 22, 2018, to merge the two companies. Now the two companies announced the deal has been terminated.
IDRAW IDRA BCRX

3
BioCryst, Idera shares halted as proposed merger called off - MarketWatch

2018-07-10 marketwatch
Shares of BioCryst Pharmaceuticals Inc. BCRX, +0.00% and Idera Pharmaceuticals Inc. IDRA, -0.72% were halted in the extended session Tuesday after BioCryst shareholders voted down a merger between the two drug companies. BioCryst shares were flat Tuesday, closing at $6.14, while Idera shares slipped 0.7% to close the session at $1.37. BioCryst said it would reimburse Idera for $6 million in transaction-related expenses as a result of terminating the merger agreement, which was announced in January.
IDRAW IDRA BCRX

1
Idera Pharmaceuticals Announces Termination of Merger Agreement with BioCryst Pharmaceuticals

2018-07-10 globenewswire
EXTON, Pa., July 10, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced today that the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) entered into by and among Idera and BioCryst on January 22, 2018, has been terminated. The Merger Agreement was terminated following the July 10, 2018 special meeting of BioCryst stockholders at which BioCryst’s stockholders voted against the proposed mergers.
IDRAW IDRA BCRX

315
Loncar Cancer Immunotherapy Index Reshuffles Listed Companies

2018-06-20 biospace
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
ZYME BLCM NLNK PIRS ARMO RCUS INO IDRAW INCY SRNE JNCE IDRA FATE MRTX CLDX

163
Institutional Top Ideas: Great Point Partners

2018-06-19 seekingalpha
Great Point Partners has high returns of late and a significantly concentrated portfolio while avoiding extreme overweighting we´ve seen with certain other funds.
SGEN DBV IDRAW IDRA MRTX CASC

97
Idera Stock Has Declined Since Failure Of Phase 2 Trial In Rare Disease, But That Wasn't The Golden Ticket Indication

2018-06-19 seekingalpha
The true value in Idera lies in the combination study using IMO-2125 and Yervoy in patients with anti-PD-1 refractory melanoma.
IDRAW IDRA BCRX

234
Institutional Top Ideas: Cormorant Asset Management

2018-06-16 seekingalpha
Cormorant Asset Management has overweighted its top 5 positions (especially first 3) and a relatively high turnover compared to other funds we´ve looked at.
OMER VSAR RXDX MDGL IDRAW IDRA GLMD

112
Idera Stock Down, Study on Dermatomyositis Candidate Fails

2018-06-13 zacks
Idera Pharmaceuticals Inc (IDRA - Free Report) announced that the phase II clinical study, evaluating its pipeline candidate, IMO-8400, for dermatomyositis — a rare inflammatory skin disease — fell short of meeting the primary endpoint.
IDRAW IDRA CRSP GHDX BCRX

97
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

2018-06-13 globenewswire
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., June 13, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), today announced that they will be presenting at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018 at 10:00 A.M. E.T.
IDRAW IDRA BCRX

72
Idera Pharmaceuticals Reports Results from Phase 2 Trial of IMO-8400 in Dermatomyositis

2018-06-12 globenewswire
EXTON, Pa., June 12, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, today announced topline results from the Phase 2 clinical trial of IMO-8400 in adult patients with dermatomyositis.
IDRAW IDRA

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...